Indeed, a Phase 1 trial combining the intra-tumoral administration of SVV with ICIs targeting PD-(L)1 and CTLA4 is anticipated to initiate the enrollment of treatment-refractory neuroendocrine neoplasms within months after the publication of this review. This evidence concerns the gene CTLA4 and neuroendocrine neoplasm.